The global mediastinal mass treatment market size was valued at USD 4.20 billion in 2024 and is expected to reach USD 6.84 billion by 2032, at a CAGR of 6.30% during the forecast period
The market growth is largely fueled by the increasing incidence of mediastinal masses, particularly primary mediastinal large B-cell lymphoma (PMBCL), along with advancements in chemotherapy, immunotherapy, and targeted treatment options
Furthermore, rising awareness among patients and healthcare providers, coupled with early diagnosis and improved treatment outcomes, is driving adoption of specialized therapies, thereby significantly boosting the industry’s growth
2 Views